Pierre E. Elisca

Array ( [id] => 13357323 [patent_doc_number] => 20180230201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => BROADLY NEUTRALIZING HUMAN ANTIBODY THAT RECOGNIZES THE RECEPTOR-BINDING POCKET OF INFLUENZA HEMAGGLUTININ [patent_app_type] => utility [patent_app_number] => 15/628544 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15628544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12979792 [patent_doc_number] => 20170342135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => Antibodies With Simultaneous Subsite Specificities To Protein and Lipid Epitopes [patent_app_type] => utility [patent_app_number] => 15/621584 [patent_app_country] => US [patent_app_date] => 2017-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12043 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15621584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13690207 [patent_doc_number] => 20170356058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-14 [patent_title] => COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS C VIRUS GENOTYPE 3 [patent_app_type] => utility [patent_app_number] => 15/618675 [patent_app_country] => US [patent_app_date] => 2017-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10154 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15618675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266419 [patent_doc_number] => 11191823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Compositions and methods for treating arenavirus infection [patent_app_type] => utility [patent_app_number] => 16/308318 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 28 [patent_no_of_words] => 20175 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16308318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14273821 [patent_doc_number] => 20190134195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-09 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS (HPV)-ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 16/306076 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59255 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227373 [patent_doc_number] => 20190125859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => INFLUENZA VIRUS VACCINATION REGIMENS [patent_app_type] => utility [patent_app_number] => 16/305841 [patent_app_country] => US [patent_app_date] => 2017-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 190786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15424451 [patent_doc_number] => 10545147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Interferon-l4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/597459 [patent_app_country] => US [patent_app_date] => 2017-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 34369 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15597459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15424451 [patent_doc_number] => 10545147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Interferon-l4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/597459 [patent_app_country] => US [patent_app_date] => 2017-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 34369 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15597459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15424451 [patent_doc_number] => 10545147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Interferon-l4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/597459 [patent_app_country] => US [patent_app_date] => 2017-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 34369 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15597459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15424451 [patent_doc_number] => 10545147 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-28 [patent_title] => Interferon-l4 (IFNL-4) protein, related nucleic acid molecules, and uses thereof [patent_app_type] => utility [patent_app_number] => 15/597459 [patent_app_country] => US [patent_app_date] => 2017-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 22 [patent_no_of_words] => 34369 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 245 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15597459 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448554 [patent_doc_number] => 09982037 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Agents for influenza neutralization [patent_app_type] => utility [patent_app_number] => 15/595407 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 35338 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338929 [patent_doc_number] => 20190151437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => COMBINATION PRIME: BOOST THERAPY [patent_app_type] => utility [patent_app_number] => 16/300014 [patent_app_country] => US [patent_app_date] => 2017-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16300014 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695509 [patent_doc_number] => 10946078 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Treatment of canine atopic dermatitis [patent_app_type] => utility [patent_app_number] => 16/097156 [patent_app_country] => US [patent_app_date] => 2017-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 21 [patent_no_of_words] => 18928 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16097156 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926385 [patent_doc_number] => 20190298830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => NEUTRALIZING HUMAN MONOCLONAL ANTIBODY 8D6 AGAINST HCV INFECTION [patent_app_type] => utility [patent_app_number] => 16/303336 [patent_app_country] => US [patent_app_date] => 2017-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11986751 [patent_doc_number] => 20170290906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-12 [patent_title] => 'VLPS Containing Ligands and Methods Related Thereto' [patent_app_type] => utility [patent_app_number] => 15/491447 [patent_app_country] => US [patent_app_date] => 2017-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 14386 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15491447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18444528 [patent_doc_number] => 11680086 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof [patent_app_type] => utility [patent_app_number] => 16/606525 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 10 [patent_no_of_words] => 17671 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 246 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132393 [patent_doc_number] => 20190100586 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => Humanized Anti-Claudin-1 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 16/086934 [patent_app_country] => US [patent_app_date] => 2017-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17266425 [patent_doc_number] => 11191829 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-07 [patent_title] => Hepatitis B treatment vaccine base on inactivated whole recombinant Hansenula polymorpha cells which expresses HBsAg and HBcAg [patent_app_type] => utility [patent_app_number] => 16/088217 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 8901 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 314 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14069441 [patent_doc_number] => 20190083608 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => RECOMBINANT HANSENULA POLYMORPHA-BASED HIGH DOSAGE HEPATITIS B VACCINE [patent_app_type] => utility [patent_app_number] => 16/088255 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088255 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501211 [patent_doc_number] => 20190194260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => LIVE ATTENUATED ZIKA VIRUS VACCINE [patent_app_type] => utility [patent_app_number] => 16/083652 [patent_app_country] => US [patent_app_date] => 2017-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16083652 [rel_patent_id] =>[rel_patent_doc_number] =>)